LU81294A1 - Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci - Google Patents

Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci Download PDF

Info

Publication number
LU81294A1
LU81294A1 LU81294A LU81294A LU81294A1 LU 81294 A1 LU81294 A1 LU 81294A1 LU 81294 A LU81294 A LU 81294A LU 81294 A LU81294 A LU 81294A LU 81294 A1 LU81294 A1 LU 81294A1
Authority
LU
Luxembourg
Prior art keywords
naltrexone
fenfluramine
anorexia
dose
appetite
Prior art date
Application number
LU81294A
Other languages
English (en)
French (fr)
Inventor
D Smith Jr
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of LU81294A1 publication Critical patent/LU81294A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU81294A 1978-05-19 1979-05-18 Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci LU81294A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90782578A 1978-05-19 1978-05-19
US90782578 1978-05-19
US2727079 1979-04-06
US06/027,270 US4217353A (en) 1978-05-19 1979-04-06 Method for inducing anorexia

Publications (1)

Publication Number Publication Date
LU81294A1 true LU81294A1 (fr) 1980-06-05

Family

ID=26702250

Family Applications (1)

Application Number Title Priority Date Filing Date
LU81294A LU81294A1 (fr) 1978-05-19 1979-05-18 Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci

Country Status (10)

Country Link
US (1) US4217353A (da)
EP (1) EP0005636A1 (da)
AU (1) AU526854B2 (da)
DK (1) DK205979A (da)
FI (1) FI791591A7 (da)
GR (1) GR68440B (da)
IT (1) IT7922846A0 (da)
LU (1) LU81294A1 (da)
PH (1) PH15271A (da)
PT (1) PT69628B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477457A (en) * 1982-10-28 1984-10-16 E. I. Du Pont De Nemours And Company Method for inducing anorexia using nalmetrene
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4478840A (en) * 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US4600718A (en) * 1984-09-18 1986-07-15 Huebner Hans F Method of treating weight loss disorders
US4546103A (en) * 1984-09-18 1985-10-08 Huebner Hans F Method of treating weight loss disorders
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4912114A (en) * 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
FI922404L (fi) * 1989-11-27 1992-05-26 Fisons Corp Hexapeptider med sulfatestergrupper.
DK0547151T3 (da) * 1990-08-29 2003-03-17 Humanetics Corp Behandlingsmåde til fremme af vægttab under anvendelse af et substitueret delta-5-androsten
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Also Published As

Publication number Publication date
PT69628B (pt) 1981-10-21
FI791591A7 (fi) 1981-01-01
AU4714379A (en) 1979-11-22
EP0005636A1 (en) 1979-11-28
AU526854B2 (en) 1983-02-03
PT69628A (fr) 1979-06-01
IT7922846A0 (it) 1979-05-18
GR68440B (da) 1981-12-30
DK205979A (da) 1979-11-20
PH15271A (en) 1982-11-02
US4217353A (en) 1980-08-12

Similar Documents

Publication Publication Date Title
EP4483957A2 (en) Pharmaceutical composition
Blackwell Adverse effects of antidepressant drugs: Part 1: Monoamine oxidase inhibitors and tricyclics
US4217353A (en) Method for inducing anorexia
TW522012B (en) Denaturants for sympathomimetic amine salts
Ban Psychopharmacology for the Aged
JP2002538106A (ja) イソバレルアミド、イソ吉草酸、または関連化合物を用いてｃｎｓ活性の調節に影響を与えることによる、痙縮および痙攣を含む様々な病状の治療
JP2002538106A5 (da)
WO2006053186A2 (en) Method for treatment of movement disorders
HUE035105T2 (en) A composition comprising nicotine and opipramole and its use
EP4251139A2 (en) Compositions and methods for treating migraine
CN1152677C (zh) 用异戊酸衍生物类cns抑制剂治疗强直、惊厥
BE898540A (fr) Procédé pour soulager les troubles moteurs extrapyramidaux.
Jones et al. Why do cholestatic patients itch?
US5998473A (en) Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester derivatives
TW202308653A (zh) 以神經活性類固醇進行治療的方法
Bania et al. Gamma‐hydroxybutyric acid tolerance and withdrawal in a rat model
BE876382A (fr) Procede pour causer de l'anorexie par administration buccale de naltrexone ou d'un sel de celle-ci
Brown Pharmacology of cocaine abuse
US6326400B1 (en) N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement
US6156795A (en) N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement
Mahmoud et al. Tramadol as an analgesic
JPH0434524B2 (da)
WO2012175894A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
Standard et al. NBAR-Buprenorphine
FR3017296A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain